China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults | Business Wire
FDA approves first deuterated drug
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
Teva's Huntington's treatment becomes first FDA-approved deuterated drug | Pharmafile
AUSTEDO 6MG - Name Patient Medical Supply Pharmaceutical Export
Teva Announces FDA Approval of AUSTEDO™ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington's Disease
Teva Finally Wins FDA Approval for Potential Huntington's Blockbuster Austedo | BioSpace
Teva's Austedo is first 'heavy hydrogen' drug to win US FDA approval
Teva settles patent dispute with Lupin over Austedo (NYSE:TEVA) | Seeking Alpha
2020 Pharma Choice DTC/DTP Silver Winner Intouch Group and Teva | PM360
Teva's Austedo (deutetrabenazine) Receives the NMPA's Approval to Treat Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults
Teva settlement prevents Lupin from launching its Austedo generic until 2033 | Fierce Pharma
Rx Item-Austedo Tab 9Mg 60 By Teva Pharma
New branded drugs helping Teva Pharm move closer to growth | Reuters
Teva forecasts 'tenfold' growth for new launch Austedo. Why don't analysts agree? | Fierce Pharma
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Austedo - FDA prescribing information, side effects and uses
Teva launches first DTC for Austedo into competitive tardive dyskinesia 2-drug market | Fierce Pharma
Austedo (deutetrabenazine) Online kaufen - Preis & Kosten | TheSocialMedwork
AUSTEDO- deutetrabenazine tablet, coated AUSTEDO- deutetrabenazine kit
Austedo | Medic
Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington's Disease - Clinical Trials Arena
Starting Patients | AUSTEDO® (deutetrabenazine) tablets
